Glenmark Pharmaceuticals Limited
GLENMARK
Rank in Stocks
#2737
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Share Price
$24.39
Last synced: 2026-10-19
Market Cap
$6.88B
Change (1 day)
-1.20%
Change (1 year)
15.69%
Country
IN
Trade Glenmark Pharmaceuticals Limited (GLENMARK)
Category
Healthcare
P/E ratio for Glenmark Pharmaceuticals Limited (GLENMARK)
P/E ratio as of October 2026 TTM: 35.54
According to Glenmark Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.54. At the end of 2024 the company had a P/E ratio of -18.46.
P/E ratio history for Glenmark Pharmaceuticals Limited from 2004 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 35.54 | -12.62% |
| 2025 | 40.67 | -320.32% |
| 2024 | -18.46 | -141.85% |
| 2023 | 44.11 | 233.08% |
| 2022 | 13.24 | -2.02% |
| 2021 | 13.52 | 80.58% |
| 2020 | 7.49 | -62.43% |
| 2019 | 19.92 | -0.14% |
| 2018 | 19.95 | -23.99% |
| 2017 | 26.25 | -17.43% |
| 2016 | 31.79 | -29.15% |
| 2015 | 44.87 | 58.83% |
| 2014 | 28.25 | 38.70% |
| 2013 | 20.37 | 12.07% |
| 2012 | 18.17 | 8.60% |
| 2011 | 16.73 | -20.90% |
| 2010 | 21.15 | 4.33% |
| 2009 | 20.28 | 7.15% |
| 2008 | 18.92 | -19.38% |
| 2007 | 23.47 | -44.77% |
| 2006 | 42.49 | 35.57% |
| 2005 | 31.35 | 57.81% |
| 2004 | 19.86 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -1.63% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.